Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report

RATIONALE: Prostate cancer along with colorectal and lung cancers accounts for 42% of cancer cases in men globally. It is the first cancer indication for which the use of active immunotherapy, Sipuleucel-T (Provenge) was granted by the FDA in 2010. This study presents a case of prostate carcinoma an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharan, Bandana, Chiliveru, Srikanth, Bagga, Jasmine, Kohli, Sakshi, Bharadwaj, Asmi, Vaid, Ashok K., Kumar, Chaitanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034657/
https://www.ncbi.nlm.nih.gov/pubmed/32080073
http://dx.doi.org/10.1097/MD.0000000000018889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034657/
https://www.ncbi.nlm.nih.gov/pubmed/32080073
http://dx.doi.org/10.1097/MD.0000000000018889

Ejemplares similares